Pseudobulbar affect in multiple sclerosis: toward the development of innovative therapeutic strategies
- PMID:16674978
- DOI: 10.1016/j.jns.2005.09.018
Pseudobulbar affect in multiple sclerosis: toward the development of innovative therapeutic strategies
Abstract
Pseudobulbar affect (PBA), a condition involving involuntary and uncontrollable episodes of crying and/or laughing, occurs frequently in patients with a variety of neurological disorders, including amyotrophic lateral sclerosis (ALS), stroke, traumatic brain injury, dementia including Alzheimer's disease, and multiple sclerosis (MS). Although PBA results in considerable distress for patients and caretakers, it is underrecognized and undertreated. Agents used to treat psychiatric disorders--particularly tricyclic antidepressants and selective serotonin reuptake inhibitors--are useful in alleviating PBA, but act on diffuse neural networks rather than targeting those involved in emotional motor expression. As a result of their nonspecific activity, these agents are associated with a range of unwanted effects that preclude many patients from using them. Dextromethorphan, a common cough suppressant, specifically targets sigma(1) receptors concentrated in the brainstem and cerebellum, thus providing the possibility of targeting regions implicated in emotional expression. When administered in a fixed combination with quinidine, dextromethorphan is effective in treating PBA in patients with ALS, and preliminary results suggest that this therapy also is effective in treating MS-related PBA.
Similar articles
- Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect.Miller A, Panitch H.Miller A, et al.J Neurol Sci. 2007 Aug 15;259(1-2):67-73. doi: 10.1016/j.jns.2006.06.030. Epub 2007 Apr 16.J Neurol Sci. 2007.PMID:17433820Review.
- Dextromethorphan/quinidine for the treatment of pseudobulbar affect.Patatanian E, Casselman J.Patatanian E, et al.Consult Pharm. 2014 Apr;29(4):264-9. doi: 10.4140/TCP.n.2014.264.Consult Pharm. 2014.PMID:24704895Review.
- Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, Vollmer TL, Mandler RN, Dietrich DW, Fletcher M, Pope LE, Berg JE, Miller A; Psuedobulbar Affect in Multiple Sclerosis Study Group.Panitch HS, et al.Ann Neurol. 2006 May;59(5):780-7. doi: 10.1002/ana.20828.Ann Neurol. 2006.PMID:16634036Clinical Trial.
- Involuntary emotional expression disorder in Alzheimer's disease - psychopharmacotherapy aspects.Mimica N, Drmić S, Presecki P.Mimica N, et al.Psychiatr Danub. 2009 Sep;21(3):425-8.Psychiatr Danub. 2009.PMID:19794369
- Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect.Haiman G, Pratt H, Miller A.Haiman G, et al.J Clin Psychopharmacol. 2009 Oct;29(5):444-52. doi: 10.1097/JCP.0b013e3181b5ae5c.J Clin Psychopharmacol. 2009.PMID:19745644
Cited by
- Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies.Jicha GA.Jicha GA.J Mol Neurosci. 2011 Nov;45(3):713-23. doi: 10.1007/s12031-011-9558-7. Epub 2011 Jun 7.J Mol Neurosci. 2011.PMID:21647712Free PMC article.Review.
- Behavioral disorders in multiple sclerosis: a comprehensive review.Jellinger KA.Jellinger KA.J Neural Transm (Vienna). 2025 Jan;132(1):1-22. doi: 10.1007/s00702-024-02816-9. Epub 2024 Sep 4.J Neural Transm (Vienna). 2025.PMID:39231817Review.
- Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.Schoedel KA, Morrow SA, Sellers EM.Schoedel KA, et al.Neuropsychiatr Dis Treat. 2014 Jun 26;10:1161-74. doi: 10.2147/NDT.S30713. eCollection 2014.Neuropsychiatr Dis Treat. 2014.PMID:25061302Free PMC article.Review.
- Dextromethorphan/quinidine: in pseudobulbar affect.Garnock-Jones KP.Garnock-Jones KP.CNS Drugs. 2011 May;25(5):435-45. doi: 10.2165/11207260-000000000-00000.CNS Drugs. 2011.PMID:21476614Review.
- Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.Jicha GA, Nelson PT.Jicha GA, et al.Neurodegener Dis Manag. 2011 Apr;1(2):141-156. doi: 10.2217/nmt.11.9.Neurodegener Dis Manag. 2011.PMID:21927623Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous